此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Baduanjin Rehabilitation for Functional Restoration in ICI-Associated Myocarditis

2026年11月3日 更新者:Jingyi Ren、China-Japan Friendship Hospital

Individualized Symptom-Limited Baduanjin Exercise for Functional Recovery in Patients Recovering From Immune Checkpoint Inhibitor-Associated Myocarditis: The B-RESTORE-ICIAM Study

Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge. Cardiotoxicity represents a major concern, among which myocarditis accounts for a considerable proportion. This condition is characterized by poor prognosis, highly heterogeneous outcomes, and a high prevalence of persistent cardiac dysfunction after the acute phase. The dual impact of myocardial injury and underlying malignancy severely compromises patients' quality of life. Currently, it remains unclear whether implementing rehabilitation strategies for this patient population can mitigate the aforementioned challenges. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of a structured rehabilitation program for convalescent patients with ICIAM.

研究概览

详细说明

Eligible patients who are suitable for rehabilitation therapy and meet the TCM syndrome differentiation criteria of "Yangqi Deficiency with Internal Retention of Phlegm and Stasis" will be screened and undergo baseline assessments. Subsequently, they will be randomly assigned in a 1:1 ratio using block randomization to either the experimental group or the control group. The experimental group will receive a rehabilitation regimen consisting of Shengxian Quyu Decoction and specialized traditional Chinese exercise therapy, while the control group will receive conventional treatment only.The pharmacological rehabilitation intervention for the experimental group involves oral administration of Shengxian Quyu Decoction. The traditional exercise regimen is designed in accordance with the FITT principle (Frequency, Intensity, Time, Type) of exercise rehabilitation. Exercise modalities may include Baduanjin, with specific frequency, duration, and intensity tailored to individual patient conditions.The total rehabilitation period is 2 weeks. A follow-up assessment will be conducted at the end of the second week to document exercise adherence and evaluate physical examination findings, laboratory test results, TCM syndrome scores, quality of life, and Major Adverse Cardiovascular Events (MACE). Extended follow-up will continue through week 4 for MACE assessment.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Chengcheng L, Dr
  • 电话号码:010-84206809
  • 邮箱:lcc77983@126.com

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国
        • 招聘中
        • China-Japan Friendship Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Aged 18 to 80 years, inclusive.
  • Malignancy confirmed by cytology or histopathology.
  • Diagnosis of ICIAM following ICI therapy.
  • Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.
  • Meet TCM syndrome differentiation criteria for "Yangqi Deficiency with Internal Retention of Phlegm and Stasis."
  • KPS score > 60, with a life expectancy > 6 months.

Exclusion Criteria:

  • Diagnosis of fulminant myocarditis or cardiac function of NYHA IV.
  • Clear evidence suggesting cardiac injury not attributable to ICIs.
  • Concurrent acute cardiovascular events or malignant arrhythmias.
  • Coexisting severe immune-related adverse events affecting other organ systems.
  • Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Rehab Arm

The pharmacological rehabilitation protocol consists of oral administration of Shengxian Quyu Decoction. The traditional Chinese exercise rehabilitation protocol is designed following the FITT (Frequency, Intensity, Time, Type) principles of exercise therapy. Exercise modalities may include Baduanjin, with specific frequency, duration, and intensity tailored to each participant's actual condition. The total treatment period is 2 weeks.

The intervention protocol comprised a pharmacological component (Shengxian Quyu therapy) and a traditional Chinese exercise rehabilitation component.The traditional Chinese exercise rehabilitation protocol is designed following the FITT (Frequency, Intensity, Time, Type) principles of exercise therapy. Exercise modalities may include Baduanjin, with specific frequency, duration, and intensity tailored to each participant's actual condition.

无干预:Control Arm

The control arm received conventional treatment.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
MACE
大体时间:2 weeks

Cardiovascular Death, Cardiac Arrest, Cardiogenic Shock, High-Grade Atrioventricular Block

2 weeks
NT-proBNP/BNP levels
大体时间:2 weeks

change in natriuretic peptide levels from baseline to Week 2

2 weeks
Change in EuroQol Visual Analogue Scale (EQ VAS) Score
大体时间:2 weeks

The EuroQol Visual Analogue Scale (EQ VAS), included in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, assesses self-rated overall health status on a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better self-rated health. The change in EQ VAS score from baseline to Week 2 will be assessed.

2 weeks

次要结果测量

结果测量
措施说明
大体时间
MACE
大体时间:2 and 4 weeks

Rates of individual MACE components

2 and 4 weeks

其他结果措施

结果测量
措施说明
大体时间
Exercise adherence
大体时间:2 weeks

Documenting patient exercise adherence

2 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2028年7月31日

研究完成 (估计的)

2028年7月31日

研究注册日期

首次提交

2025年12月1日

首先提交符合 QC 标准的

2025年12月1日

首次发布 (实际的)

2025年12月12日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2023ZD0502805-02

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅